1. Observational study of immunosuppressive treatment patterns and outcomes in primary membranous nephropathy: a multicenter retrospective analysis.
- Author
-
Artan AS, Mirioğlu Ş, Hocaoğlu RH, Turgutalp K, Güllülü Boz SE, Eren N, Dinçer MT, Uzun S, Şahin G, Kutlay S, Cevher ŞK, Dheir H, Yılmaz M, Baştürk T, Tatar E, Kurultak İ, Öztürk R, Arıkan H, Yadigar S, Tunca O, Türkmen K, Elçioğlu ÖC, Kaya B, Karakan Ş, Ayar Y, Gül CB, Yazıcı H, and Öztürk S
- Subjects
- Humans, Male, Female, Middle Aged, Retrospective Studies, Adult, Treatment Outcome, Glomerular Filtration Rate, Glucocorticoids therapeutic use, Rituximab therapeutic use, Calcineurin Inhibitors therapeutic use, Remission Induction, Cyclophosphamide therapeutic use, Registries, Drug Therapy, Combination, Glomerulonephritis, Membranous drug therapy, Immunosuppressive Agents therapeutic use
- Abstract
Background: We evaluated the efficacy of different immunosuppressive regimens in patients with primary membranous nephropathy in a large national cohort., Methods: In this registry study, 558 patients from 47 centers who were treated with at least one immunosuppressive agent and had adequate follow-up data were included. Primary outcome was defined as complete (CR) or partial remission (PR). Secondary composite outcome was at least a 50% reduction in estimated glomerular filtration (eGFR), initiation of kidney replacement therapies, development of stage 5 chronic kidney disease, or death., Results: Median age at diagnosis was 48 (IQR: 37-57) years, and 358 (64.2%) were male. Patients were followed for a median of 24 (IQR: 12-60) months. Calcineurin inhibitors (CNIs) with or without glucocorticoids were the most commonly used regimen (43.4%), followed by glucocorticoids and cyclophosphamide (GC-CYC) (39.6%), glucocorticoid monotherapy (25.8%), and rituximab (RTX) (9.1%). Overall remission rate was 66.1% (CR 26.7%, PR 39.4%), and 59 (10.6%) patients reached secondary composite outcome. Multivariate logistic regression showed that baseline eGFR (OR 1.011, 95% CI: 1.003-1.019, p = 0.007), serum albumin (OR 1.682, 95% CI: 1.269-2.231, p < 0.001), and use of RTX (OR 0.296, 95% CI: 0.157-0.557, p < 0.001) were associated with remission rates; whereas only lower baseline hemoglobin was significantly associated with secondary composite outcome (OR: 0.843, 95% CI: 0.715-0.993, p = 0.041). CYC use was significantly associated with higher remission (OR 1.534, 95% CI: 1.027-2.290, p = 0.036)., Conclusions: Higher baseline eGFR and serum albumin levels correlated with increased remission rates. Remission rates were lower in patients treated with RTX, while those on GC-CYC showed higher rates of remission. Due to the study's retrospective nature and multiple treatments used, caution is warranted in interpreting these findings., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF